Plataforma MammaPrint® BluePrint® En el Cáncer de Mama Precoz - page 11

MINDACT – Objetivo Principal:

cHigh / MP Low group- No QT, 100% compliance

• Null Hypothesis set at

92%

• 5-Year DMFS for the cHigh/MP Low group with

no ACT= 94.7%

(CI:

92.5

– 96.2%).

Excludes 92%, positive outcome met

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,2,3,4,5,6,7,8,9,10 12,13,14,15,16,17,18,19,20